Views: 1340 Downloads: 149

Harry Kurniawan Gondo^*✉ , Elizabeth Haryanti

1. Department of Obstetric and Gynecology, School of Medicine, University of Wijaya Kusuma Surabaya, Surabaya, Indonesia.
2. Internal Medicine, School of Medicine, University of Wijaya Kusuma Surabaya, Surabaya, Indonesia.

Abstract

Preeclampsia (PE) is a systemic disorder that appears during pregnancy and results in complications in more than 3-6% of deliveries in developed countries. This disease is also the largest leading cause of maternal mortality in many countries, especially in developing countries such as Indonesia. Hence, early diagnosis of preeclampsia is important in young pregnancy to decrease mortality. Recently, activin A and inhibin A were proposed as new candidates for biomarkers in early diabetes in pregnancy. However, there is no information regarding its value in pre-eclampsia and diabetic pregnancy. Herein we conduct a study to determine the value of activin-A and inhibin-A between of preeclampsia mother and a diabetes mellitus mother. Placental samples were collected from 87 mothers undergoing cesarian delivery, which were 29 samples from healthy mothers, 29 samples from diabetic mothers, and 29 samples from preeclampsia mothers. Placentas were obtained after the mother agreed to informed consent from 3 private hospitals in Surabaya. After undergoing processing and homogenizing, placenta tissue was measured for its activin-A and inhibin-A using the ELISA method. Activin-A level placental from the healthy mother group was 0.62 mIU / ml, diabetic mother group was 1.05 mIU / ml, and preeclampsia mother group was 1.23 mIU / ml. The average level of inhibin-A in healthy mothers was 0.45 mIU / ml, diabetes mother group was 0.97 mIU / ml, and preeclampsia mother group was 1.10 mIU / ml. The conclusion is that placental activin-A and inhibin-A levels both in preeclampsia pregnancy have higher values than in diabetes mothers.

Keywords: Activin-A, Diabetes mellitus, Inhibin-A, Preeclampsia

Citation Formats: